Trials / Recruiting
RecruitingNCT06287528
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.
Conditions
- Philadelphia-Negative ALL
- Philadelphia-Positive ALL
- Relapsed ALL, Adult
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia (ALL)
- Refractory Acute Lymphoid Leukemia in Relapse
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 19-28z/IL-18 CAR T cells | 19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL |
Timeline
- Start date
- 2024-02-23
- Primary completion
- 2028-02-23
- Completion
- 2028-02-23
- First posted
- 2024-03-01
- Last updated
- 2026-02-10
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06287528. Inclusion in this directory is not an endorsement.